Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma
Authors:
- Loes H. C. NissenLNLoes H. C. Nissen
- Marieke PierikMPMarieke Pierik
- Lauranne A. A. P. DerikxLDLauranne A. A. P. Derikx
- Elke de JongEJElke de Jong
- Wietske KievitWKWietske Kievit
- Tim R. A. van Den HeuvelTHTim R. A. van Den Heuvel
- Alexander R. van RosendaelARAlexander R. van Rosendael
- Elsemieke I. PlasmeijerEPElsemieke I. Plasmeijer
- Pieter DewintPDPieter Dewint
- Rob H. A. VerhoevenRVRob H. A. Verhoeven
- Lucy I. H. OverbeekLOLucy I. H. Overbeek
- Iris D. NagtegaalINIris D. Nagtegaal
- 1 November 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 23 (11) , 2018-2026
Abstract
Patients with inflammatory bowel disease (IBD) are at increased risk to develop malignant melanoma and this risk may increase with use of anti-tumor necrosis factor (TNF) therapy. Impaired survival of immunosuppressed melanoma patients is reported in transplant and rheumatology patients. This study aims to (1) identify risk factors for melanoma development in patients with IBD, (2) compare clinical characteristics of melanoma in patients with IBD to the general population, and (3) assess the influence of immunosuppressive medication on survival. We retrospectively searched the Dutch Pathology Database to identify all Dutch patients with IBD with cutaneous melanoma between January 1991 and December 2011. We then performed 2 case–control studies. To identify risk factors for melanoma development in IBD, we compared patients with IBD with melanoma to the general IBD population. To compare outcome and survival after melanoma diagnosis, we compared cases with non-IBD melanoma patients. We included 304 patients with IBD with melanoma, 1800 IBD controls, and 8177 melanoma controls. IBD cases had more extensive IBD (ulcerative colitis: pancolitis: cases 44.5% versus IBD controls without melanoma 28.1%; P < 0.01; Crohn's disease: ileal and colonic disease: cases 57.9% versus controls 48.9%; P = 0.02). Despite a lower Nodes (N)-stage in patients with IBD (N1+ 8.3% versus 18.2%; P < 0.01) with comparable Tumor (T) and Metastasis (M) stages, survival was similar between groups, regardless of immunosuppressive or anti-TNF therapy. This study showed that IBD extent is a risk factor for melanoma development. Despite the lower N-stage in patients with IBD, we could not confirm impaired survival after melanoma in patients with IBD, regardless of anti-TNF and/or thiopurine use.Keywords
This publication has 23 references indexed in Scilit:
- Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohortInternational Journal of Cancer, 2016
- European Evidence-based Consensus: Inflammatory Bowel Disease and MalignanciesJournal of Crohn's and Colitis, 2015
- Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysisClinical Gastroenterology and Hepatology, 2014
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2013
- Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel DiseaseGastroenterology, 2012
- Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel DiseaseGastroenterology, 2011
- Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel DiseaseGastroenterology, 2011
- Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysisAnnals of the Rheumatic Diseases, 2011
- Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanomaMelanoma Research, 2010
- Risk of Extra-Intestinal Cancer in Inflammatory Bowel Disease: Meta-Analysis of Population-Based Cohort StudiesAmerican Journal of Gastroenterology, 2010